NRX Pharmaceuticals (NRXP)

NRX Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

9.9M

Short interest

settlement 2026-10-15

16.8

Days to cover

+2.8 days vs prior

64.2%

Short share of volume

2026-11-02

41,499

Fails to deliver

settlement 2026-10-14

Fri 13 Nov

Next earnings

estimated date

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in NRXP is 9,949,938 shares, up 176,376 shares over the last month. Over the last 48 readings it ranged from 545,481 shares (15 August 2025) to 9,949,938 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 594K shares a day that is 16.8 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/nrxp" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	9,949,938	+1.6%	593,632	16.76
2026-09-30	9,793,940	+0.2%	700,443	13.98
2026-09-15	9,773,562	+5.1%	600,596	16.27
2026-08-31	9,296,173	+7.2%	795,238	11.69
2026-08-14	8,673,787	+32.4%	1,500,713	5.78
2026-07-31	6,552,631	+5.7%	863,825	7.59
2026-07-15	6,198,384	+14.9%	838,061	7.40
2026-06-30	5,396,019	-5.5%	1,007,329	5.36
2026-06-15	5,710,125	+14.8%	1,715,428	3.33
2026-05-29	4,975,572	+6.5%	1,647,375	3.02
2026-05-15	4,671,669	+6.0%	1,122,720	4.16
2026-04-30	4,407,012	+35.6%	1,368,047	3.22
2026-04-15	3,248,961	+29.4%	703,102	4.62
2026-03-31	2,511,228	-8.7%	1,069,722	2.35
2026-03-13	2,749,197	+11.8%	536,722	5.12
2026-02-27	2,459,826	-8.4%	521,313	4.72
2026-02-13	2,686,859	-3.4%	500,709	5.37
2026-01-30	2,782,413	-21.1%	735,544	3.78
2026-01-15	3,527,843	+92.7%	2,710,433	1.30
2025-12-31	1,831,090	+4.9%	555,925	3.29
2025-12-15	1,744,957	+38.2%	495,030	3.52
2025-11-28	1,262,366	-7.1%	434,759	2.90
2025-11-14	1,358,460	+57.8%	447,993	3.03
2025-10-31	860,796	-6.0%	473,222	1.82
2025-10-15	915,877	+20.6%	405,023	2.26
2025-09-30	759,569	+11.7%	400,062	1.90
2025-09-15	679,818	+7.4%	519,728	1.31
2025-08-29	632,714	+16.0%	548,090	1.15
2025-08-15	545,481	-11.3%	407,355	1.34
2025-07-31	614,859	-23.1%	140,271	4.38
2025-07-15	799,531	-11.3%	146,410	5.46
2025-06-30	901,880	-24.6%	239,603	3.76
2025-06-13	1,196,888	+7.5%	368,470	3.25
2025-05-30	1,113,105	+0.1%	384,400	2.90
2025-05-15	1,111,671	-8.3%	333,120	3.34
2025-04-30	1,212,742	-2.5%	85,063	14.26
2025-04-15	1,244,321	-4.4%	149,028	8.35
2025-03-31	1,302,116	+27.0%	215,897	6.03
2025-03-14	1,025,086	-12.4%	180,767	5.67
2025-02-28	1,169,750	+1.6%	257,721	4.54
2025-02-14	1,151,255	+11.5%	363,496	3.17
2025-01-31	1,032,474	-14.4%	779,014	1.33
2025-01-15	1,206,825	+87.7%	3,907,966	1.00
2024-12-31	643,000	+7.2%	1,901,924	1.00
2024-12-13	599,835	+6.0%	188,295	3.19
2024-11-29	565,801	-15.2%	207,283	2.73
2024-11-15	667,005	-2.3%	113,040	5.90
2024-10-31	682,658	+20.4%	194,291	3.51

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of NRXP volume is 64.2%, down 4.6 points over the last five sessions. Over the last 30 readings it ranged from 25.0% (24 September 2026) to 69.0% (9 October 2026). The latest reading is 11.5 points above the 30-session average of 52.7%, on 1.5M shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	946K	1.5M	64.2%	123,081
2026-10-30	3.7M	5.6M	66.2%	496,345
2026-10-29	245K	403K	60.9%	8,383
2026-10-28	232K	423K	54.9%	6,859
2026-10-27	253K	426K	59.4%	260
2026-10-26	206K	300K	68.8%	0
2026-10-23	300K	457K	65.6%	27,474
2026-10-22	287K	625K	45.9%	19,395
2026-10-21	125K	211K	59.1%	0
2026-10-20	343K	683K	50.2%	1,700
2026-10-19	333K	537K	62.0%	0
2026-10-16	345K	600K	57.5%	0
2026-10-15	363K	543K	66.9%	8,821
2026-10-14	185K	293K	63.1%	0
2026-10-13	189K	277K	68.3%	0
2026-10-12	147K	231K	63.6%	0
2026-10-09	101K	146K	69.0%	0
2026-10-08	83K	204K	40.5%	0
2026-10-07	137K	208K	65.7%	200
2026-10-06	115K	225K	51.2%	0
2026-10-05	140K	379K	36.9%	0
2026-10-02	168K	338K	49.8%	265
2026-10-01	111K	316K	35.2%	1,342
2026-09-30	208K	465K	44.9%	754
2026-09-29	101K	309K	32.7%	329
2026-09-28	121K	304K	39.8%	1,250
2026-09-25	155K	412K	37.5%	0
2026-09-24	87K	350K	25.0%	250
2026-09-23	107K	257K	41.8%	4
2026-09-22	78K	237K	32.9%	1,581

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 14 October 2026, the fails-to-deliver balance in NRXP is 41,499 shares, up 37,872 shares over the last settlement date. Over the last 30 readings it ranged from 25 shares (13 August 2026) to 97,603 shares (24 September 2026).

Settlement	Shares failed	Price	Value
2026-10-14	41,499	$2.70	$112K
2026-10-13	3,627	$2.85	$10K
2026-10-09	563	$2.89	$2K
2026-10-08	14,756	$2.90	$43K
2026-10-07	9,202	$2.94	$27K
2026-10-06	37,597	$2.87	$108K
2026-10-05	25,862	$2.91	$75K
2026-10-01	3,096	$2.92	$9K
2026-09-29	25,213	$2.87	$72K
2026-09-28	86,426	$3.00	$259K
2026-09-25	42,533	$3.03	$129K
2026-09-24	97,603	$3.16	$308K
2026-09-18	257	$3.39	$871
2026-09-17	8,894	$3.35	$30K
2026-09-16	44,905	$3.40	$153K
2026-09-14	100	$3.40	$340
2026-09-09	3,685	$3.47	$13K
2026-09-04	7,043	$3.43	$24K
2026-09-03	282	$3.46	$976
2026-09-01	925	$3.48	$3K
2026-08-31	7,546	$3.55	$27K
2026-08-28	793	$3.62	$3K
2026-08-27	58,368	$3.46	$202K
2026-08-21	7,306	$3.51	$26K
2026-08-20	59,100	$3.33	$197K
2026-08-19	19,227	$3.44	$66K
2026-08-18	65,635	$3.43	$225K
2026-08-17	25,316	$3.27	$83K
2026-08-14	6,377	$3.34	$21K
2026-08-13	25	$3.36	$84

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for NRXP in the last 90 days. The most recent filings are listed below. Latest filing: Javitt Jonathan C (Chairman and Chief Scientist) on 2024-12-17.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2024-12-17	Javitt Jonathan C	Chairman and Chief Scientist	Buy	40K	$1.17	$47K	85K
2023-08-30	Hurvitz Chaim	Director	Buy	70K	$0.29	$20K	570K
2023-08-30	Gorovitz Aaron	Director	Buy	35K	$0.32	$11K	105K
2023-08-23	Javitt Jonathan C	Chief Scientist	Buy	100K	$0.33	$33K	446K
2023-08-22	Javitt Jonathan C	Chief Scientist	Buy	200K	$0.32	$64K	346K
2022-12-16	VAN VOORHEES SETH	CHIEF FINANCIAL OFFICER	Buy	30K	$1.10	$33K	46K
2022-12-16	Willard Stephen H	CHIEF EXECUTIVE OFFICER	Buy	50K	$1.17	$59K	50K
2022-12-07	Javitt Jonathan C	Director,TenPercentOwner	Sell	400K	$1.00	$400K	12.9M
2022-11-30	Javitt Daniel C.	TenPercentOwner	Sell	8K	$1.50	$13K	9.6M
2022-11-29	Javitt Daniel C.	TenPercentOwner	Sell	14K	$1.50	$21K	9.6M
2022-11-28	Flynn Patrick John	Director	Buy	3K	$1.24	$3K	40K
2022-11-28	Flynn Patrick John	Director	Buy	3K	$1.25	$3K	38K
2022-11-28	Flynn Patrick John	Director	Buy	3K	$1.25	$3K	38K
2022-11-28	Flynn Patrick John	Director	Buy	2K	$1.25	$2K	2K
2022-11-28	Flynn Patrick John	Director	Buy	3K	$1.25	$3K	40K
2022-11-25	VAN VOORHEES SETH	CHIEF FINANCIAL OFFICER	Buy	7K	$1.11	$8K	16K
2022-11-25	VAN VOORHEES SETH	CHIEF FINANCIAL OFFICER	Buy	7K	$1.11	$8K	16K
2022-11-25	VAN VOORHEES SETH	CHIEF FINANCIAL OFFICER	Buy	9K	$1.12	$10K	9K
2022-11-25	VAN VOORHEES SETH	CHIEF FINANCIAL OFFICER	Buy	600	$1.10	$660	9K
2022-11-18	Hurvitz Chaim	Director	Buy	40K	$1.10	$44K	500K
2022-11-17	Javitt Daniel C.	TenPercentOwner	Sell	33K	$1.05	$35K	9.7M
2022-11-17	Hurvitz Chaim	Director	Buy	172K	$1.08	$186K	460K
2022-11-16	Javitt Daniel C.	TenPercentOwner	Sell	134K	$1.02	$136K	9.7M
2022-11-16	Hurvitz Chaim	Director	Buy	288K	$0.99	$285K	288K
2022-11-11	Javitt Daniel C.	TenPercentOwner	Sell	49K	$1.01	$50K	9.8M
2022-07-29	Javitt Daniel C.	TenPercentOwner	Sell	784K	$1.01	$792K	9.9M
2022-07-01	Javitt Daniel C.	TenPercentOwner	Gift	2.0M	$0.00	$0	10.7M
2022-06-07	Javitt Daniel C.	TenPercentOwner	Sell	86K	$0.65	$56K	12.7M
2022-06-06	Javitt Daniel C.	TenPercentOwner	Sell	116K	$0.67	$77K	12.7M
2022-06-03	Javitt Daniel C.	TenPercentOwner	Sell	244K	$0.70	$171K	12.9M
2022-06-01	Javitt Jonathan C	Chief Scientist	Buy	100K	$58.00	$5.8M	146K
2022-06-01	Javitt Jonathan C	Chief Scientist	Buy	100K	$0.58	$58K	146K
2021-09-15	Besthof Robert	Chief Comm. & Patient Officer	Sell	40K	$11.76	$470K	24K
2021-09-02	Daigneault Alessandra	General Counsel & Secretary	Exercise or conversion	18K	$3.07	$57K	18K
2021-09-02	Daigneault Alessandra	General Counsel & Secretary	Exercise or conversion	13K	$3.07	$40K	32K
2021-08-26	McMaster Herbert Raymond	Director	Exercise or conversion	18K	$2.22	$41K	18K
2021-08-23	Daigneault Alessandra	General Counsel & Secretary	Sell	34K	$13.11	$442K	0
2021-08-19	Daigneault Alessandra	General Counsel & Secretary	Exercise or conversion	27K	$3.07	$84K	34K
2021-08-16	Besthof Robert	Chief Comm. & Patient Officer	Exercise or conversion	64K	$0.20	$13K	64K
2021-07-16	Javitt Daniel C.	10% owner	Gift	435K	price not stated in the filing	not stated	13.1M
2021-07-16	Javitt Daniel C.	TenPercentOwner	Gift	435K	price not stated in the filing	not stated	13.5M
2021-05-24	Gorovitz Aaron	Director	Grant	8K	price not stated in the filing	not stated	8K
2021-05-24	Gorovitz Aaron	Director	Grant	8K	price not stated in the filing	not stated	8K
2021-05-24	Flynn Patrick John	Director	Grant	35K	price not stated in the filing	not stated	35K
2021-05-24	Daigneault Alessandra	General Counsel & Secretary	Grant	6K	price not stated in the filing	not stated	6K
2021-05-24	Flynn Patrick John	Director	Grant	362K	price not stated in the filing	not stated	362K
2021-05-24	Flynn Patrick John	Director	Grant	35K	price not stated in the filing	not stated	35K
2021-05-24	Glied Sharon	Director	Grant	13K	price not stated in the filing	not stated	13K
2021-05-24	Gorovitz Aaron	Director	Grant	8K	price not stated in the filing	not stated	8K
2021-05-24	Gorovitz Aaron	Director	Grant	17K	price not stated in the filing	not stated	17K
2021-05-24	Hurvitz Chaim	Director	Grant	208K	price not stated in the filing	not stated	208K
2021-05-24	Hurvitz Chaim	Director	Grant	1.4M	price not stated in the filing	not stated	1.4M
2021-05-24	Javitt Daniel C.	TenPercentOwner	Grant	14.0M	price not stated in the filing	not stated	14.0M
2021-05-24	Javitt Jonathan C	Chief Executive Officer	Grant	46K	price not stated in the filing	not stated	46K
2021-05-24	Javitt Jonathan C	Chief Executive Officer	Grant	1.4M	price not stated in the filing	not stated	1.4M
2021-05-24	Javitt Jonathan C	Chief Executive Officer	Grant	13.3M	price not stated in the filing	not stated	13.3M
2021-05-24	Troy Daniel	Director	Grant	43K	price not stated in the filing	not stated	43K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

No holder on file reports 5% or more of NRXP in its latest filing.

Filed	Form	Holder	Shares	Of class	Event
2026-05-15	13G/Ano. 2	Anson Funds Management LP	1.7M	4.9%	2026-03-31
2026-05-15	13G/Ano. 2	Anson Management GP LLC	1.7M	4.9%	2026-03-31
2026-05-15	13G/Ano. 2	Tony Moore	1.7M	4.9%	2026-03-31
2026-05-15	13G/Ano. 2	Anson Advisors Inc.	1.7M	4.9%	2026-03-31
2026-05-15	13G/Ano. 2	Amin Nathoo	1.7M	4.9%	2026-03-31
2026-05-15	13G/Ano. 2	Moez Kassam	1.7M	4.9%	2026-03-31

13F holders

Tracked managers holding NRXP at their latest 13F. JSON

4 of the 30 tracked managers held NRXP at their latest 13F, $3.1M in total at quarter-end prices. Citadel Advisors is the largest at $2.8M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 0 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Citadel Advisors	2026-06-30	680K	$2.8M	0.00%	new
Renaissance Technologies	2026-06-30	39K	$158K	0.00%	new
Two Sigma Investments	2026-06-30	26K	$108K	0.00%	new
Millennium Management	2026-06-30	12K	$50K	0.00%	new

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

NRX Pharmaceuticals in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows NRX Pharmaceuticals (NRXP), SEC CIK 1719406, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-17.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2024-12-17.JSON and CSV
Company record: EDGAR filing index for CIK 1719406Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Other company pages

Datasets

Frequently Asked Questions

How much of NRXP is sold short?

9,949,938 shares were held short at the 2026-10-15 settlement, 16.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is NRXP's daily short volume?

On 2026-11-02, 946,368 of the 1,474,664 NRXP shares reported to FINRA were sold short, 64.2% of the day's reported volume. Short volume is a flow for one day, not a position.

Does NRXP have fails to deliver?

The SEC's latest file shows 41,499 NRXP shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.

Are NRXP insiders buying or selling?

No open-market insider trades were reported for NRXP in the last 90 days. The most recent filings are listed below. Latest filing: Javitt Jonathan C (Chairman and Chief Scientist) on 2024-12-17.

Who owns 5% or more of NRXP?

No holder on file reports 5% or more of NRXP in its latest filing.

Which tracked 13F managers own NRXP?

4 of the 30 tracked 13F managers held NRXP shares at their latest filing, $3.1M in all. The largest: Ken Griffin's Citadel Advisors (680K shares, $2.8M), Renaissance Technologies (39K shares, $158K), Two Sigma Investments (26K shares, $108K), Izzy Englander's Millennium Management (12K shares, $50K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.